Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

20 Jul 2023

Abstract excerpt

// Daniel Morillo 1 , Gala Vega 1 and Victor Moreno 2 1 Division of Hematology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain 2 Division of Oncology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain Correspondence to: Victor Moreno, email: victor.moreno@startmadrid.com Keywords: cyclin-dependent kinases (CDK); CDK9; hematological malignancies Received: April 18, 2023 Accepted:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37552223
DOI: 10.18632/oncotarget.28473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignanciesPMID 37552223Read ↗

The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignanciesSemantic proximity Read ↗

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read ↗

Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016)Semantic proximity Read ↗

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphomaSemantic proximity Read ↗

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read ↗

Targeting cell cycle regulators in hematologic malignanciesSemantic proximity Read ↗

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developmentsSemantic proximity Read ↗

Targeting CDK9 for Anti-Cancer TherapeuticsSemantic proximity Read ↗

CDK9: A key player in cancer and other diseasesSemantic proximity Read ↗

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitorsSemantic proximity Read ↗

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising ApproachesSemantic proximity Read ↗

CDK9 inhibitors in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.